Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 500

1.

Impact of Concurrent Indolent Lymphoma on the Clinical Outcome of Newly Diagnosed Diffuse Large B-Cell Lymphoma.

Wang Y, Link BK, Witzig TE, Maurer MJ, Allmer C, King RL, Feldman AL, Habermann TM, Ansell SM, Slager SL, Cerhan JR, Nowakowski GS.

Blood. 2019 Jul 26. pii: blood.2019000858. doi: 10.1182/blood.2019000858. [Epub ahead of print]

PMID:
31350266
2.

Variable global distribution of cell-of-origin from the ROBUST phase 3 study in diffuse large B-cell lymphoma.

Nowakowski GS, Chiappella A, Witzig TE, Scott DW, Spina M, Gascoyne RD, Zhang L, Russo J, Kang J, Zhang J, Xu Y, Vitolo U.

Haematologica. 2019 Jun 20. pii: haematol.2019.220475. doi: 10.3324/haematol.2019.220475. [Epub ahead of print]

3.

Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.

Wang Y, Farooq U, Link BK, Larson MC, King RL, Maurer MJ, Allmer C, Hefazi M, Thompson CA, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Ansell SM, Cerhan JR, Nowakowski GS.

J Clin Oncol. 2019 Jul 20;37(21):1819-1827. doi: 10.1200/JCO.19.00014. Epub 2019 Jun 6.

PMID:
31170029
4.

Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma.

Wang Y, Maurer MJ, Larson MC, Allmer C, Feldman AL, Bennani NN, Thompson CA, Porrata LF, Habermann TM, Witzig TE, Ansell SM, Slager SL, Nowakowski GS, Cerhan JR.

Br J Haematol. 2019 May 28. doi: 10.1111/bjh.15997. [Epub ahead of print]

PMID:
31135975
5.

Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma.

Wu X, Stenson M, Abeykoon J, Nowakowski K, Zhang L, Lawson J, Wellik L, Li Y, Krull J, Wenzl K, Novak AJ, Ansell SM, Bishop GA, Billadeau DD, Peng KW, Giles F, Schmitt DM, Witzig TE.

Blood. 2019 Jul 25;134(4):363-373. doi: 10.1182/blood.2018874560. Epub 2019 May 17.

PMID:
31101621
6.

Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.

Nowakowski GS, Feldman T, Rimsza LM, Westin JR, Witzig TE, Zinzani PL.

Blood Cancer J. 2019 May 16;9(6):48. doi: 10.1038/s41408-019-0208-6. Review.

7.

Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.

Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA.

Leuk Lymphoma. 2019 Apr 24:1-8. doi: 10.1080/10428194.2019.1602268. [Epub ahead of print]

PMID:
31014142
8.

Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma.

St-Pierre F, Broski SM, LaPlant BR, Ristow K, Maurer MJ, Macon WR, Habermann TM, Ansell SM, Thompson CA, Micallef INM, Nowakowski GS, Witzig TE.

Am J Hematol. 2019 Jul;94(7):786-793. doi: 10.1002/ajh.25493. Epub 2019 May 16.

PMID:
31006875
9.

Acalabrutinib for mantle cell lymphoma.

Witzig TE, Inwards D.

Blood. 2019 Jun 13;133(24):2570-2574. doi: 10.1182/blood.2019852368. Epub 2019 Apr 9. Review.

PMID:
30967367
10.

Work-Life Balance Solutions for Physicians-It's All About You, Your Work, and Others.

Witzig TE, Smith SM.

Mayo Clin Proc. 2019 Apr;94(4):573-576. doi: 10.1016/j.mayocp.2018.11.021. No abstract available.

PMID:
30947830
11.

Host genetic variation in tumor necrosis factor and nuclear factor-κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study.

Wang Y, Habermann TM, Wang SS, Maurer MJ, Sarangi V, Link BK, Feldman AL, Inwards DJ, Witzig TE, Cozen W, Rothman N, Asmann Y, Slager SL, Cerhan JR.

Am J Hematol. 2019 Jun;94(6):E153-E155. doi: 10.1002/ajh.25451. Epub 2019 Mar 15. No abstract available.

PMID:
30815899
12.

The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells.

Abeykoon JP, Paludo J, Nowakowski KE, Stenson MJ, King RL, Wellik LE, Wu X, Witzig TE.

Blood Cancer J. 2019 Feb 26;9(3):24. doi: 10.1038/s41408-019-0188-6. No abstract available.

13.

Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.

Castellino A, Pulido JS, Johnston PB, Ristow KM, Nora Bennani N, Inwards DJ, Macon WR, Micallef INM, King RL, Salomao DR, Witzig TE, Habermann TM, Nowakowski GS.

Am J Hematol. 2019 Mar;94(3):291-298. doi: 10.1002/ajh.25350. Epub 2018 Dec 5.

PMID:
30516868
14.

Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma.

Han JJ, O'byrne M, Stenson MJ, Maurer MJ, Wellik LE, Feldman AL, McPhail ED, Witzig TE, Gupta M.

Blood Cancer J. 2018 Nov 12;8(11):110. doi: 10.1038/s41408-018-0138-8.

15.

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.

Castellino A, Chiappella A, LaPlant BR, Pederson LD, Gaidano G, Macon WR, Inghirami G, Reeder CB, Tucci A, King RL, Congiu A, Foran JM, Pavone V, Rivera CE, Spina M, Ansell SM, Cavallo F, Molinari AL, Ciccone G, Habermann TM, Witzig TE, Vitolo U, Nowakowski GS.

Blood Cancer J. 2018 Nov 8;8(11):108. doi: 10.1038/s41408-018-0145-9.

16.

Acute coronary syndromes in patients with active hematologic malignancies - Incidence, management, and outcomes.

Park JY, Guo W, Al-Hijji M, El Sabbagh A, Begna KH, Habermann TM, Witzig TE, Lewis BR, Lerman A, Herrmann J.

Int J Cardiol. 2019 Jan 15;275:6-12. doi: 10.1016/j.ijcard.2018.10.008. Epub 2018 Oct 5.

PMID:
30318297
17.

Primary systemic amyloidosis in patients with Waldenström macroglobulinemia.

Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, Sidana S, Tandon N, Rajkumar SV, Dingli D, Go R, Lacy MQ, Kourelis T, Witzig TE, Inwards D, Buadi F, Gonsalves W, Habermann T, Johnston P, Nowakowski G, Kyle RA, Kumar S, Kapoor P.

Leukemia. 2019 Mar;33(3):790-794. doi: 10.1038/s41375-018-0286-7. Epub 2018 Oct 12. No abstract available.

PMID:
30315235
18.

Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma.

Wenzl K, Manske MK, Sarangi V, Asmann YW, Greipp PT, Schoon HR, Braggio E, Maurer MJ, Feldman AL, Witzig TE, Slager SL, Ansell SM, Cerhan JR, Novak AJ.

Blood Cancer J. 2018 Oct 9;8(10):97. doi: 10.1038/s41408-018-0130-3.

19.

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.

Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE.

Blood. 2018 Nov 22;132(21):2240-2248. doi: 10.1182/blood-2018-02-835496. Epub 2018 Sep 27.

20.

Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?

Thanarajasingam G, Maurer MJ, Habermann TM, Nowakowski GS, Bennani NN, Thompson CA, Cerhan JR, Witzig TE.

Nutr Cancer. 2018 Oct;70(7):1088-1090. doi: 10.1080/01635581.2018.1502328. Epub 2018 Sep 20.

PMID:
30235018
21.

The association of physical activity before and after lymphoma diagnosis with survival outcomes.

Pophali PA, Ip A, Larson MC, Rosenthal AC, Maurer MJ, Flowers CR, Link BK, Farooq U, Feldman AL, Allmer C, Slager SL, Witzig TE, Habermann TM, Cohen JB, Cerhan JR, Thompson CA.

Am J Hematol. 2018 Dec;93(12):1543-1550. doi: 10.1002/ajh.25288. Epub 2018 Oct 17.

PMID:
30230581
22.

Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia.

Abeykoon JP, Zanwar S, Ansell SM, Winters J, Gertz MA, King RL, Murray D, Habermann T, Dingli D, Muchtar E, Go RS, Leung N, Inwards DJ, Buadi FK, Dispenzieri A, Lacy MQ, Lin Y, Gonsalves WI, Kourelis T, Witzig TE, Thompson C, Vincent Rajkumar S, Kyle RA, Kumar S, Kapoor P.

Am J Hematol. 2018 Nov;93(11):1384-1393. doi: 10.1002/ajh.25254. Epub 2018 Oct 2.

PMID:
30121949
23.

A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.

Padrnos L, Ernst B, Dueck AC, Kosiorek HE, Ginos BF, Toro A, Johnston PB, Habermann TM, Leis JF, Mikhael JR, Nowakowski GS, Colgan J, Porrata L, Ansell SM, Witzig TE, Reeder C.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):664-672.e2. doi: 10.1016/j.clml.2018.06.013. Epub 2018 Jun 15.

PMID:
30104176
24.

Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.

Paulus A, Manna A, Akhtar S, Paulus SM, Sharma M, Coignet MV, Jiang L, Roy V, Witzig TE, Ansell SM, Allan J, Furman R, Aulakh S, Manochakian R, Ailawadhi S, Chanan-Khan AA, Sher T.

Br J Haematol. 2018 Oct;183(2):196-211. doi: 10.1111/bjh.15515. Epub 2018 Aug 6.

PMID:
30080238
25.

History of autoimmune conditions and lymphoma prognosis.

Kleinstern G, Maurer MJ, Liebow M, Habermann TM, Koff JL, Allmer C, Witzig TE, Nowakowski GS, Micallef IN, Johnston PB, Inwards DJ, Thompson CA, Feldman AL, Link BK, Flowers C, Slager SL, Cerhan JR.

Blood Cancer J. 2018 Aug 1;8(8):73. doi: 10.1038/s41408-018-0105-4.

26.

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.

McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM.

Haematologica. 2018 Nov;103(11):1899-1907. doi: 10.3324/haematol.2018.190157. Epub 2018 Jun 14.

27.

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

Maurer MJ, Ghesquières H, Link BK, Jais JP, Habermann TM, Thompson CA, Haioun C, Allmer C, Johnston PB, Delarue R, Micallef IN, Peyrade F, Inwards DJ, Ketterer N, Farooq U, Fitoussi O, Macon WR, Molina TJ, Syrbu S, Feldman AL, Slager SL, Weiner GJ, Ansell SM, Cerhan JR, Salles GA, Witzig TE, Tilly H, Nowakowski GS.

J Clin Oncol. 2018 Jun 1;36(16):1603-1610. doi: 10.1200/JCO.2017.76.5198. Epub 2018 Apr 19.

28.

Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.

Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, King RL, Koehler AB, Reeder CB, Buadi FK, Dispenzieri A, Lacy MQ, Dingli D, Witzig TE, Go RS, Gonsalves WI, Kourelis T, Warsame R, Leung N, Habermann TM, Hayman S, Lin Y, Kyle RA, Rajkumar SV, Gertz MA, Kapoor P.

Ann Hematol. 2018 Aug;97(8):1417-1425. doi: 10.1007/s00277-018-3311-z. Epub 2018 Apr 3.

PMID:
29610969
29.

Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era.

King RL, Nowakowski GS, Witzig TE, Scott DW, Little RF, Hong F, Gascoyne RD, Kahl BS, Macon WR.

Blood Cancer J. 2018 Feb 28;8(3):27. doi: 10.1038/s41408-018-0064-9.

30.

Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease.

Majumder S, Mohapatra S, Lennon RJ, Piovezani Ramos G, Postier N, Gleeson FC, Levy MJ, Pearson RK, Petersen BT, Vege SS, Chari ST, Topazian MD, Witzig TE.

Clin Gastroenterol Hepatol. 2018 Dec;16(12):1947-1953. doi: 10.1016/j.cgh.2018.02.049. Epub 2018 Mar 8.

PMID:
29526692
31.

Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.

Inwards DJ, Fishkin PA, LaPlant BR, Drake MT, Kurtin PJ, Nikcevich DA, Wender DB, Lair BS, Witzig TE.

Ann Oncol. 2019 Feb 1;30(2):346. doi: 10.1093/annonc/mdx814. No abstract available.

32.

A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.

Sonbol MB, Hilal T, Dueck AC, Rosenthal AC, Conley CR, Kosiorek HE, Ginos BF, Gano KM, Nichols CS, Leis JF, Johnston PB, Habermann TM, Northfelt DW, Bergsagel PL, Inwards DJ, Witzig TE, Ansell SM, Reeder CB.

Leuk Lymphoma. 2018 Sep;59(9):2128-2134. doi: 10.1080/10428194.2017.1416368. Epub 2018 Jan 10.

PMID:
29320913
33.

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.

Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa LJ, Bermudez Silva CD, Zhu J, Belada D, Bouabdallah K, Kattan JG, Kuruvilla J, Kim WS, Larouche JF, Ogura M, Ozcan M, Fayad L, Wu C, Fan J, Louveau AL, Voi M, Cavalli F.

Ann Oncol. 2018 Mar 1;29(3):707-714. doi: 10.1093/annonc/mdx764.

PMID:
29253068
34.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY.

N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.

35.

Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma.

Bernatsky S, Velásquez García HA, Spinelli JJ, Gaffney P, Smedby KE, Ramsey-Goldman R, Wang SS, Adami HO, Albanes D, Angelucci E, Ansell SM, Asmann YW, Becker N, Benavente Y, Berndt SI, Bertrand KA, Birmann BM, Boeing H, Boffetta P, Bracci PM, Brennan P, Brooks-Wilson AR, Cerhan JR, Chanock SJ, Clavel J, Conde L, Cotenbader KH, Cox DG, Cozen W, Crouch S, De Roos AJ, de Sanjose S, Di Lollo S, Diver WR, Dogan A, Foretova L, Ghesquières H, Giles GG, Glimelius B, Habermann TM, Haioun C, Hartge P, Hjalgrim H, Holford TR, Holly EA, Jackson RD, Kaaks R, Kane E, Kelly RS, Klein RJ, Kraft P, Kricker A, Lan Q, Lawrence C, Liebow M, Lightfoot T, Link BK, Maynadie M, McKay J, Melbye M, Molina TJ, Monnereau A, Morton LM, Nieters A, North KE, Novak AJ, Offit K, Purdue MP, Rais M, Riby J, Roman E, Rothman N, Salles G, Severi G, Severson RK, Skibola CF, Slager SL, Smith A, Smith MT, Southey MC, Staines A, Teras LR, Thompson CA, Tilly H, Tinker LF, Tjonneland A, Turner J, Vajdic CM, Vermeulen RCH, Vijai J, Vineis P, Virtamo J, Wang Z, Weinstein S, Witzig TE, Zelenetz A, Zeleniuch-Jacquotte A, Zhang Y, Zheng T, Zucca M, Clarke AE.

Lupus Sci Med. 2017 Nov 12;4(1):e000187. doi: 10.1136/lupus-2016-000187. eCollection 2017.

36.

Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression.

Tracy SI, Habermann TM, Feldman AL, Maurer MJ, Dogan A, Perepu US, Syrbu S, Ansell SM, Thompson CA, Weiner GJ, Nowakowski GS, Allmer C, Slager SL, Witzig TE, Cerhan JR, Link BK.

Haematologica. 2018 Feb;103(2):297-303. doi: 10.3324/haematol.2017.176511. Epub 2017 Nov 23.

37.

MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.

Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, Halvorson AE, Gonsalves WI, Dingli D, Fang H, Rajkumar SV, Lacy MQ, He R, Kourelis T, Reeder CB, Novak AJ, McPhail ED, Viswanatha DS, Witzig TE, Go RS, Habermann TM, Buadi FK, Dispenzieri A, Leung N, Lin Y, Thompson CA, Hayman SR, Kyle RA, Kumar SK, Kapoor P.

Am J Hematol. 2018 Feb;93(2):187-194. doi: 10.1002/ajh.24955. Epub 2017 Nov 17.

38.

Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma.

Hu G, Dasari S, Asmann YW, Greipp PT, Knudson RA, Benson HK, Li Y, Eckloff BW, Jen J, Link BK, Jiang L, Sidhu JS, Wellik LE, Witzig TE, Bennani NN, Cerhan JR, Boddicker RL, Feldman AL.

Leukemia. 2018 Feb;32(2):565-569. doi: 10.1038/leu.2017.309. Epub 2017 Oct 13. No abstract available.

39.

Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.

Cerhan JR, Link BK, Habermann TM, Maurer MJ, Feldman AL, Syrbu SI, Thompson CA, Farooq U, Novak AJ, Slager SL, Allmer C, Lunde JJ, Macon WR, Inwards DJ, Johnston PB, Micallef INM, Nowakowski GS, Ansell SM, Kay NE, Weiner GJ, Witzig TE.

Int J Epidemiol. 2017 Dec 1;46(6):1753-1754i. doi: 10.1093/ije/dyx119. No abstract available.

40.

Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.

Thanarajasingam G, Maurer MJ, Farooq U, Johnston PB, Thompson CA, Bennani NN, Ansell SM, Porrata LF, Macon WR, Syrbu SI, Cerhan JR, Habermann TM, Link BK, Witzig TE, Nowakowski GS.

Br J Haematol. 2018 Oct;183(1):149-152. doi: 10.1111/bjh.14922. Epub 2017 Sep 29. No abstract available.

PMID:
28961306
41.

A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.

Dispenzieri A, D'Souza A, Gertz MA, Laumann K, Wiseman G, Lacy MQ, LaPlant B, Buadi F, Hayman SR, Kumar SK, Dingli D, Hogan WJ, Ansell SM, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Johnston PB, Litzow MR, Witzig TE.

Bone Marrow Transplant. 2017 Oct;52(10):1372-1377. doi: 10.1038/bmt.2017.164. Epub 2017 Sep 4.

PMID:
28869617
42.

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma.

Tracy SI, Maurer MJ, Witzig TE, Drake MT, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Johnston PB, Micallef IN, Allmer C, Macon WR, Weiner GJ, Slager SL, Habermann TM, Link BK, Cerhan JR.

Blood Cancer J. 2017 Aug 25;7(8):e595. doi: 10.1038/bcj.2017.70.

43.

Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.

Paludo J, Abeykoon JP, Kumar S, Shreders A, Ailawadhi S, Gertz MA, Kourelis T, King RL, Reeder CB, Leung N, Kyle RA, Buadi FK, Habermann TM, Dingli D, Witzig TE, Dispenzieri A, Lacy MQ, Go RS, Lin Y, Gonsalves WI, Warsame R, Lust JA, Rajkumar SV, Ansell SM, Kapoor P.

Br J Haematol. 2017 Oct;179(1):98-105. doi: 10.1111/bjh.14826. Epub 2017 Aug 8.

PMID:
28786474
44.

Pseudo-monoclonal gammopathy: a report of four cases.

Jawad MD, Go RS, Witzig TE, Mikhael JR, Ravindran A, Murrray DL.

Haematologica. 2017 Nov;102(11):e466-e469. doi: 10.3324/haematol.2017.171694. Epub 2017 Aug 3. No abstract available.

45.

Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells.

Shenoy N, Bhagat T, Nieves E, Stenson M, Lawson J, Choudhary GS, Habermann T, Nowakowski G, Singh R, Wu X, Verma A, Witzig TE.

Blood Cancer J. 2017 Jul 21;7(7):e587. doi: 10.1038/bcj.2017.65.

46.

Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.

Witzig TE, Luigi Zinzani P, Habermann TM, Tuscano JM, Drach J, Ramchandren R, Kalayoglu Besisik S, Takeshita K, Casadebaig Bravo ML, Zhang L, Fu T, Goy A.

Am J Hematol. 2017 Oct;92(10):E575-E583. doi: 10.1002/ajh.24854. Epub 2017 Aug 28.

47.

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance).

Witzig TE, LaPlant B, Habermann TM, McPhail E, Inwards DJ, Micallef IN, Colgan JP, Nowakowski GS, Ansell SM, Johnston PB.

Blood Cancer J. 2017 Jun 23;7(6):e576. doi: 10.1038/bcj.2017.57. No abstract available.

48.
49.

Maintenance Lenalidomide for Large-Cell Lymphoma: Who Really Benefits?

Witzig TE.

J Clin Oncol. 2017 Aug 1;35(22):2459-2460. doi: 10.1200/JCO.2017.73.2578. Epub 2017 May 17. No abstract available.

PMID:
28514184
50.

Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.

Epperla N, Pham AQ, Burnette BL, Wiseman GA, Habermann TM, Macon WR, Ansell SM, Inwards DJ, Micallef IN, Johnston PB, Markovic SN, Porrata LF, Colgan JP, Ristow KM, Nowakowski GS, Witzig TE.

Br J Haematol. 2017 Aug;178(3):427-433. doi: 10.1111/bjh.14688. Epub 2017 May 3.

PMID:
28466487

Supplemental Content

Loading ...
Support Center